Martin Belkin, DO
Neurology · Farmington Hills, MINPI 1861462129
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $565,955 of the $711,693 with a category attached, or 79.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.0%. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,022 payments — averaging $696.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$157K
- Biogen$109K
- Genentech USA, Inc.$92K
- TG Therapeutics, Inc.$79K
- Sanofi$74K
- AstraZeneca$65K
- plus $136K from 29 others
Across 812 payments — averaging $6219.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.5M
- AbbVie$1M
- Novartis$823K
- TG Therapeutics, Inc.$371K
- F. Hoffmann-la Roche AG$353K
- Roche Products Limited$341K
- plus $674K from 6 others
What the payments were for
- Consulting fees$99,69014%
- Speaking & faculty fees$565,95580%
- Travel & lodging$23,7063%
- Food & beverage$22,2263%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 166 | $156,791 |
| Biogen | 140 | $108,865 |
| Genentech USA, Inc. | 103 | $91,519 |
| TG Therapeutics, Inc. | 72 | $79,442 |
| Sanofi | 80 | $74,278 |
| AstraZeneca | 58 | $64,769 |
| E.r. Squibb & Sons, L.L.C. | 22 | $35,669 |
| Amgen(2 entities) | 39 | $27,596 |
| Bristol Myers Squibb | 50 | $27,586 |
| Argenx US, Inc. | 9 | $14,296 |
| AbbVie(2 entities) | 72 | $9,367 |
| Novartis | 82 | $8,102 |
| Teva Pharmaceuticals USA, Inc. | 32 | $6,894 |
| Merck Kgaa | 2 | $3,300 |
| Genentech, Inc. | 3 | $1,981 |
| Pfizer | 14 | $208 |
| Otsuka America Pharmaceutical, Inc. | 17 | $136 |
| Eisai Inc. | 7 | $132 |
| Sumitomo Pharma America, Inc. | 11 | $117 |
| Supernus Pharmaceuticals, Inc. | 11 | $117 |
| UCB, Inc. | 3 | $99 |
| Biohaven Pharmaceuticals, Inc. | 4 | $81 |
| Avanir Pharmaceuticals, Inc. | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 5 | $51 |
| Acorda Therapeutics, Inc | 3 | $41 |
| Catalyst Pharmaceuticals, Inc. | 2 | $31 |
| Grifols USA, LLC | 2 | $30 |
| Lilly USA, LLC | 2 | $24 |
| MDD US Operations, LLC | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Promius Pharma LLC | 1 | $14 |
| Zogenix Inc. | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$711,693 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 109 | $867,846 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 82 | $664,963 |
| Kesimpta PenOfatumumab | 43 | $424,942 |
| CopaxoneGlatiramer Acetate | 47 | $335,590 |
| AubagioTeriflunomide | 28 | $320,725 |
| AmpyraDalfampridine | 44 | $252,762 |
| VumerityDiroximel Fumarate | 25 | $213,587 |
| Teriflunomide | 93 | $212,054 |
| TysabriNatalizumab | 16 | $153,110 |
| GilenyaFingolimod Hcl | 15 | $141,228 |
| TecfideraDimethyl Fumarate | 13 | $120,816 |
| KeppraLevetiracetam | 26 | $117,612 |
| Dalfampridine ErDalfampridine | 192 | $95,251 |
| LamictalLamotrigine | 26 | $72,270 |
| GlatopaGlatiramer Acetate | 27 | $63,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Vumerity, Tysabri, Tecfidera | $108,865 | $1,355,359163 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $6,894 | $335,59047 claims |
| SanofiAubagio | $74,278 | $320,72528 claims |
| Acorda Therapeutics, IncAmpyra | $41 | $252,76244 claims |
| NovartisGilenya | $8,102 | $141,22815 claims |
| UCB, Inc.Vimpat, Briviact | $99 | $80,27441 claims |
| PfizerNurtec Odt | $208 | $55,62031 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $51 | $55,48927 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $58 | $21,29213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Farmington Hills
- Aaron EllenbogenFarmington Hills$1.6M
- Richard TroschFarmington Hills$1.2M
- Yang Mao DraayerFarmington Hills$372K
- Lauren AymenFarmington Hills$349K
- Daniel SingerFarmington Hills$306K
- Mark KachadurianFarmington Hills$258K
- Mark SilvermanFarmington Hills$225K
- Jonathan FellowsFarmington Hills$164K
- William BoudourisFarmington Hills$152K
- Nader WarraFarmington Hills$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.